REVOLUTIONARY CANCER RELAPSE DETECTION IN A SIMPLE BLOOD TEST NON-INVASIVE | PAIN FREEINNOVATIVE

Aspect liquid biopsy supports targeted treatment decisions by detecting cancer recurrence earlier using cfDNA biomarkers through an innovative yet simple blood test.

VISIT OUR WEBSITE TO LEARN MORE  CLINICALLABS.COM.AU/ASPECT

Visit our website to learn more clinicallabs.com.au/aspect

REVOLUTIONARY CANCER RELAPSE DETECTION IN A SIMPLE BLOOD TESTNON-INVASIVE | PAIN FREE | INNOVATIVE

Aspect Liquid Biopsy supports targeted treatment decisions bydetecting cancer recurrence earlier using cfDNA biomarkersthrough an innovative yet simple blood test.

GP

Australian Clinical Labs is the first national private laboratory in Australia to introduce the innovation of liquid biopsy.

Aspect Liquid Biopsy uses the latest technology to

analyse a bio-fluid sample to assess the genetic makeup

of a tumour. The process for patients is the same as a

standard blood test which is non-invasive and pain free,

saving time and money without the need to undergo an

invasive procedure or hospital admission.

Unlike traditional biopsies which can be invasive, painful

and require recovery time, Aspect Liquid Biopsy is a non-

invasive, simple blood test which can be used to monitor

cances including melanoma, lung and colorectal using

cell-free DNA biomarkers in blood.

Earlier detection can support better treatment decisions.

Aspect Liquid Biopsy can improve patient outcomes and

increase survival rates by detecting cancer recurrence

earlier than the current conventional methods, such as

imaging, invasive techniques and blood tumour markers.

Why is liquid biopsy so important?

Aspect Liquid Biopsy has been made possible by

advances in sequencing the human genome. Using

the tumour-derived circulating DNA, Aspect Liquid

Biopsy allows the detection of the tumour somatic

mutations that commonly occur in cancers, enabling the

identification of the actionable gene targets (e.g. EGFR in

lung cancer, KRAS in colorectal and BRAF in melanoma),

thus correlating with clinical parameters and facilitating

monitoring and treatment selection.

Cancer genetic profile in a simple blood test

Supporting the most effective treatment decisions.

After a traditional biopsy, a tissue

sample taken may not contain

tumour tissue, or may not qualify

for DNA mutation testing due

to degraded DNA quality, or an

insufficient quantity to run the assay.

Over time, resistant clones

containing other variants may grow

out of the tumour - variants that

were not detected from the initial

solid tissue biopsy. This makes the

genetic makeup of the original

tumour historical.

Aspect Liquid Biopsy enables

the discovery of those new DNA

markers in the blood in real time,

supporting the most effective

treatment decisions.

How to order

When should it be ordered?

What is the cost?

How is it collected?

Health Practitioners can order Aspect Liquid Biopsy for

cancer patients using the Aspect request form. Some

required information is listed on the form, including

the type of cancer, whether it is a new diagnosis and

if the patient is on anti-tumour therapy (if known).

Health Practitioners can download the Aspect

Liquid Biopsy form on the Clinical Labs website at

clinicallabs.com.au/aspect

Health Practitioners can order Aspect Liquid Biopsy

for cancer patients any time during management

stages.

Out of pocket fee of $550.

(No Medicare rebate available)

This test requires two

10ml blood samples which

can be taken at any of our

collection centres.

When will results be available?

Results will be available

after 5-7 business days

from the sample receipt

date.

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the

National Clinical Director of Molecular Genetic Pathology at Australian Clinical

Labs. Associate Professor Saad’s PhD research allowed her to gain unique

experience in a wide range of biochemical, molecular genetics and cancer

targeting. She has published several articles both locally and internationally.

At Clinical Labs, Assoc. Prof Mirette Saad leads the Molecular Genetic testing

for hereditary disorders, personalised drug therapy, somatic mutation and

gene expression profile testing in cancer.

Assoc. Prof. Mirette SaadMBBS (HONS), MD (HONS), MAACB, FRCPA, PHD

National Clinical Director of Molecular Genetic Pathology,

Australian Clinical Labs

“A Personalised Medicine approach in cancer care is not new. What is new, however, is our ability to predict cancer recurrence based on the differences between individuals at molecular levels. This means that we can sub-group, or sub-stratify patients in a more meaningful way, with the potential to modify therapeutic regimes to match their individual genetic profile.”

P: (03) 9538 6777

E: Mirette.Saad@clinicallabs.com.au

www.clinicallabs.com.au

ACLM

AR-R

EQ-N

AT-0

027.

7 4

/18

ACL

ZPAD

0060

1300 453 688VIC NSW SA NT

Western Australia

1300 367 674

Requesting Doctor:

Provider Number:

Address:

Suburb:

Given Name:

Date of Birth:

Address:

Suburb:

Phone:

Hospital Name:

Signature:

Gender: .

Gene Target Tick if Required

c MALE

c Non-small cell lung cancer

c Melanoma

c FEMALE

Patient Details

Test Required

Clinical Details

Is this a new diagnosis?

Has the patient been treated with systemic anti-tumour therapy?

Previous somatic mutationdetected (if known):

Patient Stage:

Tumour Type:

Clinical Information

Date:

Post Code:State:

Medicare Number:

Surname:

c Colorectal Panel - RAS, PIK3CA, BRAF (EGFR)

c Lung Panel - KRAS, PIK3CA, BRAF, EGFR (incl. T790M)

c Melanoma Panel - NRAS, BRAF

c Colorectal carcinoma

x

For a current list of centres, please visit our website www.clinicallabs.com.au

or contact us on 1300 453 688 (VIC, NSW, SA & NT) or on 1300 367 674 (WA

only). All of our collection centres across Victoria, New South Wales and Western

Australia collect for Aspect Liquid Biopsy. Collection centres in South Australia

and Northern Territory require appointments for the Aspect Liquid Biopsy Test.

Please contact us to find your nearest collection centre and book an appointment.

1 Please complete patient details, clinical information,

patient informed consent and clinician details in FULL

2 Collect Two Tubes of Whole Blood into Roche, Cell

Free DNA tubes (White cap: Used also for Harmony)

– Mix well & gently

3 Transport at Ambient Room temperature – Do not centrifuge

In some infrequent cases, it will not be possible to generate an Aspect Liquid Biopsy result. Should this occur you may choose to provide a new blood sample for testing. No additional fees will be incurred for the second test. In the event that you decide not to submit an additional sample for testing, Australian Clinical Labs will refund the full test fee paid. Results will be made available to you through your nominated doctor.

Instructions For Collectors Collection Centres

c Yes

c Yes

c No

c No

Referring Clinician Details Copy Doctor Details

Patient Informed Consent

Referring Clinician Signature:

Name:

Address:

Suburb:

Phone:

Copy Hospital:

Fax:

State: Post Code:

x Date:

Patient Signature:x Date:

My signature on this form indicates that I understand the informed consent and give permission to Australian Clinical Labs to perform the laboratory Aspect Liquid Biopsy tests selected. I have had the opportunity to ask questions and discuss the capabilities and limitations with my healthcare provider. I have been informed that there is no Medicare Rebate for this test and agree to pay the out-of-pocket fee.

Fax:

Post Code:

Phone:

State:

This test has a fee of $550 (per panel).

Please tick one: c Invoice c Pay over the phone (receipt_______________)

x2

Visit our website to learn more

clinicallabs.com.au/aspect

REVOLUTIONARY CANCER RELAPSE DETECTION IN A SIMPLE BLOOD TEST NON-INVASIVE | PAIN FREEINNOVATIVE

Aspect liquid biopsy supports targeted treatment decisions by detecting cancer recurrence earlier using cfDNA biomarkers through an innovative yet simple blood test.

VISIT OUR WEBSITE TO LEARN MORE  CLINICALLABS.COM.AU/ASPECT

ACLM

AR-B

F-NA

T-01

76.8

4/1

8AC

LZBC

H001

7

The word aspect is defined as a unique view or perspective.

Through Aspect Liquid Biopsy, we can offer an unprecedented view

of the genetic signatures of cancer relapse, allowing clinicians to

catch it early and make the most effective treatment decisions.

Advanced Technology

Highly Sensitive and Specific Assay

Expertise in Diagnostic Oncology

Accurate and Comprehensive Reports

High-Quality, Personalised Cancer Care

Rapid Turnaround Time

VISIT OUR WEBSITE TO LEARN MORE

CLINICALLABS.COM.AU/ASPECT

1. Fleischhacker M et al., (2007) Biochem Biophys Acta 1775; 181-232.2. John T et al., (2017) Asia-Pacific J of Clin Oncol 13; 296-303.

3. Thierry AR et al., (2014) Nat Med 20; 430-35.4. Newman AM et al., (2014) Nat Med 20; 548-54.

5. Thress et al., (2015) Lung Cancer 90; 509-15.6. Wu YL et al., (2017) Br J cancer 116; 175-85.

7. Tie et al., (2016) Sci Transl Med 8; 346ra92.8. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-small cell lung cancer (7 April 2017)